 |
|
Inhibition of metastases in mice
Experiments were carried out in inbred G57B1/6 mice of 8-10 weeks of age weighing 20-22g on the following cancer cell-lines: meta-stasizing Lewis lung carcinoma (3LL-HH) injected into the spleen, B-16 mouse melanoma injected into muscle tissue and HCR-25 human colon carcinoma xenograft injected into the spleen. The administration of Avemar began 24 hours after the tumor cells were implanted.
Results: metastasis formation in liver decreased by 71% (significant) following treatment with Avemar for the 3LL-HH tumor cells. For HCR-25 human colon carcinoma, 50 days of treatment with Avemar resulted in a significant (50%) decrease in both the number and size of liver metastases as well as the size of the primary tumor injected into spleen. The number of metastases in B-16 melanoma decreased by 85% (significant) after 21 days of treatment [1]. Control groups were used for all cancer types.
Conclusions: Avemar's tumour-inhibiting effect can be taken as a fact.
|
 |
|
 |
